摘要
目的系统分析临床应用丹参川芎嗪联合依达拉奉治疗急性脑梗塞的效果和安全性。方法计算机检索Cochrane图书馆临床对照试验资料库、PubMed、CNKI、维普期刊、万方数据库、中国生物医学文献数据库中有关丹参川芎嗪联合依达拉奉治疗急性脑梗塞的临床随机对照研究,并手动检索相关杂志、文献,检索时间自成立之日至2018年12月20日。确定纳入和排除标准,由两人独立筛选文献,提取数据及进行文献质量评价,使用系统评价软件Review Manager 5.3进行数据分析。结果最终纳入25项临床随机对照研究,共计2460例,治疗组1231例,对照组1229例,14项研究描述了不良反应的情况。Meta分析结果表明,相比对照组,丹参川芎嗪联合依达拉奉治疗急性脑梗死总有效率更高[OR=3.47;95%CI(2.79,4.32);P<0.00001],痊愈率优于对照组[OR=2.21;95%CI(1.77,2.75);P<0.00001];神经功能保护作用优于对照组[OR=4.28;95%CI(2.73,5.82);P<0.00001];日常生活能力评分改善效果高于对照组[OR=13.26;95%CI(6.67,19.84);P<0.0001];在不良反应方面,治疗组与对照组无统计学意义[OR=0.73;95%CI(0.37,1.47);P=0.38]。结论相比对照组,丹参川芎嗪联合依达拉奉治疗急性脑梗死总有效率、治愈率、神经功能保护、日常生活能力改善等方面效果较好,不良反应方面欠缺更多研究。但本次研究纳入文献质量一般,具有局限性,上述结论需要更多高质量、大样本、多中心研究支持。
Objective To systematically review the clinical efficacy and safety of salvia ligustrazine combined with edaravone in treating acute cerebral infarction.Methods The Cochrane Library,PubMed,CNKI,VIP Database,Wanfang Data and CBMdisc databases were electronically and other relevant journals were manually searched from the inception of the database to December 20th,2018 to collect randomized controlled trials(RCTs)of salvia ligustrazine combined with edaravone in treating acute cerebral infarction.The inclusion and exclusion criteria were determined.Two reviewers independently screened the literature,extracted data and assessed the quality of literature.Then the systematic review was performed by using RevMan 5.3 software.Results A total of 25 studies involving 2460 patients(1231 patients in the treatment group and 1229 patients in the control group)were included,and adverse events were found in 14 studies.The meta-analysis showed that compared with the control group,salvia ligustrazine combined with edaravone had higher total effective rate[OR=3.47,95%Cl(2.79,4.32),P<0.00001],higher cure rate[OR=2.21,95%Cl(1.77,2.75),P<0.00001],more effective in protecting neurological function[OR=4.28,95%Cl(2.73,5.82),P<0.00001],better improvement in activity of daily living[OR=13.26,95%Cl(6.67,19.84),P<0.0001].There was no significant difference in the adverse events between the treatment and control groups[OR=0.73,95%Cl(0.37,1.47),P=0.38).Conclusion Compared with the control group,salvia ligustrazine combined with edaravone has better effect on the total effective rate,cure rate,neurological function protection and improvement of daily living activity in the treatment of acute cerebral infarction.However,there is a lack of studies on adverse events.Due to the limited quality of the included studies,more high-quality,large-sample,multi-centered studies are needed to support the conclusion.
作者
周晓磊
黄淑芳
易芹
庞庆禄
ZHOU Xiao-lei;HUANG Shu-fang;YI Qin;PANG Qing-lu(Beijing University of Chinese Medicine,Beijing 100029)
出处
《世界中西医结合杂志》
2020年第2期250-256,300,共8页
World Journal of Integrated Traditional and Western Medicine
关键词
丹参川芎嗪
依达拉奉
急性脑梗死
随机对照
META分析
系统评价
Salvia miltiorrhiza and Ligustrazine
Edaravone
Acute cerebral infarction
Randomized controlled trial
Meta-analysis
System review
